Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis
NCT04118010 is a phase 4 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is completed. It studies Inulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3 in Cystic Fibrosis and Dysbiosis. The registry lists an enrollment of 40 participants at 1 site in 1 country. The registry lists a start date of 13 Mar 2020 and a primary completion date of 31 Dec 2022.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04118010 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Emory University |
| Enrollment | 40 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Cystic Fibrosis and Dysbiosis |
| Drugs | Inulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3 |
| Start | 13 Mar 2020 |
| Primary completion | 31 Dec 2022 |
| Study completion | 31 Dec 2022 |
| Last update posted | 7 Feb 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Vin Tangpricha, MD
Emory University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory Clinic
Atlanta
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04118010
Each answer restates registry values shown on this page.
What is NCT04118010?
NCT04118010 is a phase 4 interventional trial sponsored by Emory University. It studies Inulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3 in Cystic Fibrosis and Dysbiosis.
Who leads NCT04118010?
The registry names Vin Tangpricha, MD (principal investigator, Emory University) as the overall official.
Where does NCT04118010 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04118010 study?
The registered drug and biological interventions are Inulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3.
When did NCT04118010 end?
The registry lists a primary completion date of 31 Dec 2022 and a study completion date of 31 Dec 2022. The sponsor last updated the record on 7 Feb 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.